董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Christopher J. O’Connell 董事长兼首席执行官 52 825.82万(USD) 未持股 2019-04-04
Linda Baddour 董事 60 13.43万(USD) 未持股 2019-04-04
JoAnn A. Reed 董事 63 32.00万(USD) 未持股 2019-04-04
Christopher A. Kuebler 董事 65 30.75万(USD) 未持股 2019-04-04
Laurie H. Glimcher 董事 67 29.00万(USD) 未持股 2019-04-04
Thomas P. Salice 董事 59 33.65万(USD) 未持股 2019-04-04
Gary E. Hendrickson 董事 62 13.28万(USD) 未持股 2019-04-04
Michael J. Berendt 董事 70 29.80万(USD) 未持股 2019-04-04
Edward Conard 董事 62 31.50万(USD) 未持股 2019-04-04
Flemming Ornskov 董事 61 29.45万(USD) 未持股 2019-04-04

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Christopher J. O’Connell 董事长兼首席执行官 52 825.82万(USD) 未持股 2019-04-04
Michael C. Harrington -- 高级副总裁,全球市场 -- 241.94万(USD) 未持股 2019-04-04
Robert G. Carson -- 企业发展高级副总裁 -- 378.17万(USD) 未持股 2019-04-04
Francis Kim -- 高级副总裁,全球运营 -- 241.51万(USD) 未持股 2019-04-04
Sherry L. Buck 高级副总裁兼首席财务官 -- 262.58万(USD) 未持股 2019-04-04

董事简历

中英对照 |  中文 |  英文
Christopher J. O’Connell

Christopher J. O’Connell先生,为Medtronic,Inc.之执行副总裁及美敦力之恢复性治疗集团之总裁.O`Connell先生负责全球美敦力之脊柱╱骨科及生物制剂、神经调节、糖尿病及手术技术业务单位.O`Connell先生为本集团提供整体策略方向及全球营运监督相关业务,以及以美敦力之整体策略领导整合本集团活动.O`Connell先生于一九九四年加入美敦力,并曾于该公司担任多项领导职位.于二零零六年至二零零九年期间,O`Connell先生担任驻加利福利亚Northridge糖尿病业务之高级副总裁及总裁.于二零零五年至二零零六年期间,彼担任驻华盛顿Redmond之Medtronic Physio-Control之总裁.O`Connell先生亦曾于美敦力之心脏节律疾病管理业务担任重要领导职务,包括销售及市场推广副总裁及病人管理业务之副总裁╱总经理.此外,O`Connell先生作为企业策略副总裁及投资者关系董事领导重要公司职能.于加入美敦力前,O`Connell先生于化工银行之公司财务单位任职.O`Connell先生于一九八九年在西北大学获得学士学问,并于一九九四年在哈佛大学获得工商管理硕士学位.


Christopher J. O’Connell has been Executive Vice President and Group President, Restorative Therapies Group since August 2009. Prior to that, he was Senior Vice President and President, Diabetes from October 2006 to August 2009 President of Medtronic’s Emergency Response Systems division from May 2005 to October 2006 and Vice President of Sales and Marketing of Medtronic’s Cardiac Rhythm Disease Management division from November 2001 to May 2005. Mr. O’Connell has served in various management positions since joining the Company in 1994.
Christopher J. O’Connell先生,为Medtronic,Inc.之执行副总裁及美敦力之恢复性治疗集团之总裁.O`Connell先生负责全球美敦力之脊柱╱骨科及生物制剂、神经调节、糖尿病及手术技术业务单位.O`Connell先生为本集团提供整体策略方向及全球营运监督相关业务,以及以美敦力之整体策略领导整合本集团活动.O`Connell先生于一九九四年加入美敦力,并曾于该公司担任多项领导职位.于二零零六年至二零零九年期间,O`Connell先生担任驻加利福利亚Northridge糖尿病业务之高级副总裁及总裁.于二零零五年至二零零六年期间,彼担任驻华盛顿Redmond之Medtronic Physio-Control之总裁.O`Connell先生亦曾于美敦力之心脏节律疾病管理业务担任重要领导职务,包括销售及市场推广副总裁及病人管理业务之副总裁╱总经理.此外,O`Connell先生作为企业策略副总裁及投资者关系董事领导重要公司职能.于加入美敦力前,O`Connell先生于化工银行之公司财务单位任职.O`Connell先生于一九八九年在西北大学获得学士学问,并于一九九四年在哈佛大学获得工商管理硕士学位.
Christopher J. O’Connell has been Executive Vice President and Group President, Restorative Therapies Group since August 2009. Prior to that, he was Senior Vice President and President, Diabetes from October 2006 to August 2009 President of Medtronic’s Emergency Response Systems division from May 2005 to October 2006 and Vice President of Sales and Marketing of Medtronic’s Cardiac Rhythm Disease Management division from November 2001 to May 2005. Mr. O’Connell has served in various management positions since joining the Company in 1994.
Linda Baddour

Linda Baddour于2007年加入PRA,担任其执行副总裁兼首席财务官。加入PRA以前,从2002年到2007年,Baddour女士在PPD担任首席财务官,从1997年到2002年,担任首席会计官,从1995年到1997年,担任公司财务总管。Baddour女士在威明顿市的北卡罗来大学(University of North Carolina)获得工商管理硕士学位,他还是一位注册会计师。


Linda Baddour has served as a Director of the Company since September 2018. From June 2007 to September 2018 Ms. Baddour served as Executive Vice President and Chief Financial Officer of PRA Health Sciences. From May 2002 to May 2007 she was the Chief Financial Officer and Accounting Officer and from 1997 to April 2007 she was the Chief Accounting Officer at Pharmaceutical Product Development, Inc. From 1995 to 1997 Ms. Baddour was the Corporate Controller at Pharmaceutical Product Development, Inc. From 1980 to 1995 she served as Controller of Cooperative Bank for Savings Inc.
Linda Baddour于2007年加入PRA,担任其执行副总裁兼首席财务官。加入PRA以前,从2002年到2007年,Baddour女士在PPD担任首席财务官,从1997年到2002年,担任首席会计官,从1995年到1997年,担任公司财务总管。Baddour女士在威明顿市的北卡罗来大学(University of North Carolina)获得工商管理硕士学位,他还是一位注册会计师。
Linda Baddour has served as a Director of the Company since September 2018. From June 2007 to September 2018 Ms. Baddour served as Executive Vice President and Chief Financial Officer of PRA Health Sciences. From May 2002 to May 2007 she was the Chief Financial Officer and Accounting Officer and from 1997 to April 2007 she was the Chief Accounting Officer at Pharmaceutical Product Development, Inc. From 1995 to 1997 Ms. Baddour was the Corporate Controller at Pharmaceutical Product Development, Inc. From 1980 to 1995 she served as Controller of Cooperative Bank for Savings Inc.
JoAnn A. Reed

JoAnn A. Reed,自2007年5月担任董事,并于2007年11月担任审计委员会成员。目前,她担任医疗保健服务方面的咨询顾问。她曾在Medco Health Solutions公司担任高级副总裁,负责金融事务,并担任财务总监,直至2008年3月卸任。该公司是一家药品福利管理企业。在于1988年进入Medco公司后,她曾担任与金融和会计有关的多个职务,包括于1992年担任高级副总裁,负责金融事务,并于1996年担任财务总监。在进入Medco公司前,她曾在Aetna/American Re-Insurance Co., CBS公司、Standard and Poor公司和Unisys/Timeplex公司担任多个金融方面的职务。目前,她在Mallinckrodt公司和Waters 公司担任董事。她还在印第安纳的圣母圣玛丽学院(St. Mary’s College of Notre Dame)担任理事。


JoAnn A. Reed has served as a Director of the Company since May 2006. Ms. Reed has been a health care services consultant since 2009. From April 2008 to April 2009 she was an advisor to the Chief Executive Officer of Medco Health Solutions, Inc. From 2002 to March 2008 Ms. Reed served as Senior Vice President, Finance and Chief Financial Officer of Medco Health Solutions, Inc. From 1992 to 2002 she served as Senior Vice President, Finance of Medco Health Solutions, Inc. She joined Medco Containment Services, Inc. in 1988. Before come to here, her was employment with CBS, Inc., Aetna/American Re-insurance Co., Standard and Poor’s Financial Services LLC, and Unisys/Timeplex.
JoAnn A. Reed,自2007年5月担任董事,并于2007年11月担任审计委员会成员。目前,她担任医疗保健服务方面的咨询顾问。她曾在Medco Health Solutions公司担任高级副总裁,负责金融事务,并担任财务总监,直至2008年3月卸任。该公司是一家药品福利管理企业。在于1988年进入Medco公司后,她曾担任与金融和会计有关的多个职务,包括于1992年担任高级副总裁,负责金融事务,并于1996年担任财务总监。在进入Medco公司前,她曾在Aetna/American Re-Insurance Co., CBS公司、Standard and Poor公司和Unisys/Timeplex公司担任多个金融方面的职务。目前,她在Mallinckrodt公司和Waters 公司担任董事。她还在印第安纳的圣母圣玛丽学院(St. Mary’s College of Notre Dame)担任理事。
JoAnn A. Reed has served as a Director of the Company since May 2006. Ms. Reed has been a health care services consultant since 2009. From April 2008 to April 2009 she was an advisor to the Chief Executive Officer of Medco Health Solutions, Inc. From 2002 to March 2008 Ms. Reed served as Senior Vice President, Finance and Chief Financial Officer of Medco Health Solutions, Inc. From 1992 to 2002 she served as Senior Vice President, Finance of Medco Health Solutions, Inc. She joined Medco Containment Services, Inc. in 1988. Before come to here, her was employment with CBS, Inc., Aetna/American Re-insurance Co., Standard and Poor’s Financial Services LLC, and Unisys/Timeplex.
Christopher A. Kuebler

Christopher A. Kuebler,2001年12月他担任公司董事。他现在也在Waters公司董事会任职,Waters是一家分析技术服务公司。1997年1月至2005年12月, 他担任Covance 公司董事会主席,Covance是一家药物开发服务公司。1994年11月至2004年12月,他担任CEO。1993年3月至1994年11月担任雅培公司欧洲运营副总裁,雅培是一家多样化健康保健公司。1986年1月至1993年3月, 他在雅培制药部担任过很多职位,曾担任部门副总裁,在这之前他负责欧洲市场营销。他也曾在Squibb公司和Monsanto医疗保健公司任职。他拥有加州大学生物科学学士学位。


Christopher A. Kuebler has served as a Director of the Company since May 2006. He has been an independent director and investor since 2006. He served as Chairman and Chief Executive Officer of Covance Inc. and its predecessor companies from November 1994 to December 2004 and as Chairman during 2005. Prior to joining Covance, Inc., Mr. Kuebler spent nearly 20 years in the pharmaceutical industry at Abbott Laboratories, Squibb, Inc. and the Monsanto Company.
Christopher A. Kuebler,2001年12月他担任公司董事。他现在也在Waters公司董事会任职,Waters是一家分析技术服务公司。1997年1月至2005年12月, 他担任Covance 公司董事会主席,Covance是一家药物开发服务公司。1994年11月至2004年12月,他担任CEO。1993年3月至1994年11月担任雅培公司欧洲运营副总裁,雅培是一家多样化健康保健公司。1986年1月至1993年3月, 他在雅培制药部担任过很多职位,曾担任部门副总裁,在这之前他负责欧洲市场营销。他也曾在Squibb公司和Monsanto医疗保健公司任职。他拥有加州大学生物科学学士学位。
Christopher A. Kuebler has served as a Director of the Company since May 2006. He has been an independent director and investor since 2006. He served as Chairman and Chief Executive Officer of Covance Inc. and its predecessor companies from November 1994 to December 2004 and as Chairman during 2005. Prior to joining Covance, Inc., Mr. Kuebler spent nearly 20 years in the pharmaceutical industry at Abbott Laboratories, Squibb, Inc. and the Monsanto Company.
Laurie H. Glimcher

Laurie H. Glimcher自1998年1月起担任公司董事。Glimcher是Weill Cornell Medical College的Stephen and Suzanne Weiss院长,以及Cornell University医疗事务教务长。Glimcher从1991年到2011年担任Harvard School of Public Health免疫学Irene Heinz Given教授;以及Harvard Medical School医学教授。Glimcher是Bristol-Myers Squibb Company董事。她是 American Academy of Arts and Sciences研究员;National Academy of Sciences成员以及Institutes of Medicine of the National Academy of Sciences成员。


Laurie H. Glimcher has served as a Director of the Company since January 1998. Dr. Glimcher is the President and Chief Executive Officer of the Dana-Farber Cancer Institute, the Principal Investigator and Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine, Harvard Medical School. From January 2012 to June 2016 Dr. Glimcher served as the Stephen and Suzanne Weiss Dean of the Weill Cornell Medical College and Provost for Medical Affairs of Cornell University. From 1991 through 2011 Dr. Glimcher served as the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School.
Laurie H. Glimcher自1998年1月起担任公司董事。Glimcher是Weill Cornell Medical College的Stephen and Suzanne Weiss院长,以及Cornell University医疗事务教务长。Glimcher从1991年到2011年担任Harvard School of Public Health免疫学Irene Heinz Given教授;以及Harvard Medical School医学教授。Glimcher是Bristol-Myers Squibb Company董事。她是 American Academy of Arts and Sciences研究员;National Academy of Sciences成员以及Institutes of Medicine of the National Academy of Sciences成员。
Laurie H. Glimcher has served as a Director of the Company since January 1998. Dr. Glimcher is the President and Chief Executive Officer of the Dana-Farber Cancer Institute, the Principal Investigator and Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine, Harvard Medical School. From January 2012 to June 2016 Dr. Glimcher served as the Stephen and Suzanne Weiss Dean of the Weill Cornell Medical College and Provost for Medical Affairs of Cornell University. From 1991 through 2011 Dr. Glimcher served as the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School.
Thomas P. Salice

Thomas P. Salice,从1996年10月开始担任董事,是审计委员会成员和薪酬委员会主席。她是SFW 资本合作公司共同创建者和主管,SFW 是一家私人股权公司。他从2005年1月开始SFW 资本合作公司常务董事。1989年6月至2004年12月,他在AEA 投资公司担任过各种职位,包括常务董事、总裁、CEO和副董事长。他拥有哈佛大学工商管理硕士学位。他也是Waters 公司董事和私人企业Agknowledge控股公司、工业动力控股有限公司、MD Buyline公司和斯派克公司董事。


Thomas P. Salice has served as a Director of the Company since July 1994. Mr. Salice is a co-founder and managing member of SFW Capital Partners, LLC, a private equity firm. He has served as a Managing Member of SFW Capital Partners, LLC since January 2005. From June 1989 to December 2004 Mr. Salice served in a variety of capacities with AEA Investors, Inc., including Managing Director, President and Chief Executive Officer and Vice-Chairman. Mr. Salice is Director of several privately held companies: Filtec and Gerson Lehrman Group, Inc.
Thomas P. Salice,从1996年10月开始担任董事,是审计委员会成员和薪酬委员会主席。她是SFW 资本合作公司共同创建者和主管,SFW 是一家私人股权公司。他从2005年1月开始SFW 资本合作公司常务董事。1989年6月至2004年12月,他在AEA 投资公司担任过各种职位,包括常务董事、总裁、CEO和副董事长。他拥有哈佛大学工商管理硕士学位。他也是Waters 公司董事和私人企业Agknowledge控股公司、工业动力控股有限公司、MD Buyline公司和斯派克公司董事。
Thomas P. Salice has served as a Director of the Company since July 1994. Mr. Salice is a co-founder and managing member of SFW Capital Partners, LLC, a private equity firm. He has served as a Managing Member of SFW Capital Partners, LLC since January 2005. From June 1989 to December 2004 Mr. Salice served in a variety of capacities with AEA Investors, Inc., including Managing Director, President and Chief Executive Officer and Vice-Chairman. Mr. Salice is Director of several privately held companies: Filtec and Gerson Lehrman Group, Inc.
Gary E. Hendrickson

Gary E. Hendrickson,自2011年6月以来,他担任威士伯集团(The Valspar Corporation,一个全球油漆和涂料制造商)的总裁兼首席执行官。从2008年2月到2011年6月,他担任总裁兼首席运营官。从2005年到2008年2月,他担任高级副总裁负责几个重要业务部门。他担任威士伯集团(The Valspar Corporation)的总裁负责亚太地区、部门副总裁负责全球木材涂料以及总裁负责亚太地区(2004年到2005年)。从1999年到2004年,他担任威士伯集团(The Valspar Corporation)的公司副总裁和亚太地区总裁。自2009年以来,他成为威士伯集团(The Valspar Corporation)的董事会的成员。自2012年以来,他被任命为董事长。他担任我们薪酬委员会主席并成为我们公司治理和提名委员会的成员。


Gary E. Hendrickson has served as a Director of the Company since September 2018. He has been an independent director and investor since June 2017. From June 2011 to June 2017 he served as the Chief Executive Officer of The Valspar Corporation; and from June 2012 to June 2017 he also served as the Chairman; and from February 2008 to June 2017 he also served as the President. From February 2001 to June 2008 Mr. Hendrickson served in the following positions of The Valspar Corporation: Chief Operating Officer, Group Vice President of Global Wood Coatings, Senior Vice President of Architectural, Global Wood Coatings and Federal Business Units and Corporate Vice President and President of Asia Pacific.
Gary E. Hendrickson,自2011年6月以来,他担任威士伯集团(The Valspar Corporation,一个全球油漆和涂料制造商)的总裁兼首席执行官。从2008年2月到2011年6月,他担任总裁兼首席运营官。从2005年到2008年2月,他担任高级副总裁负责几个重要业务部门。他担任威士伯集团(The Valspar Corporation)的总裁负责亚太地区、部门副总裁负责全球木材涂料以及总裁负责亚太地区(2004年到2005年)。从1999年到2004年,他担任威士伯集团(The Valspar Corporation)的公司副总裁和亚太地区总裁。自2009年以来,他成为威士伯集团(The Valspar Corporation)的董事会的成员。自2012年以来,他被任命为董事长。他担任我们薪酬委员会主席并成为我们公司治理和提名委员会的成员。
Gary E. Hendrickson has served as a Director of the Company since September 2018. He has been an independent director and investor since June 2017. From June 2011 to June 2017 he served as the Chief Executive Officer of The Valspar Corporation; and from June 2012 to June 2017 he also served as the Chairman; and from February 2008 to June 2017 he also served as the President. From February 2001 to June 2008 Mr. Hendrickson served in the following positions of The Valspar Corporation: Chief Operating Officer, Group Vice President of Global Wood Coatings, Senior Vice President of Architectural, Global Wood Coatings and Federal Business Units and Corporate Vice President and President of Asia Pacific.
Michael J. Berendt

Michael J. Berendt,1998年3月开始担任董事,是独立董事和投资人。2006年3月至2011年7月,他担任Aegera 疗法公司总裁兼CEO。2004年8月至2005年12月,他担任企业技术研究常务董事。2000年11月至2004年8月担任AEA投资公司常务董事。他在医药行业从事了18年,从1982年-2000年,担任各种高级管理职位,包括拜耳公司医药研究部门高级副总裁、辉瑞公司要去研发主管。他也曾担任Onyx制药公司、利亚德基因公司、催化剂生物科学和北极星神经学董事。


Michael J. Berendt has served as a Director of the Company since March 1998. Since December 2016 Dr. Berendt has been a life sciences industry consultant. From November 2013 to November 2016 Dr. Berendt was the Chief Executive Officer and Chief Scientist of Telesta Therapeutics. From July 2011 to November 2013 Dr. Berendt was a life sciences industry consultant. From March 2006 to July 2011 Dr. Berendt served as the President and Chief Executive Officer of Aegera Therapeutics Inc. From August 2004 to December 2005 Dr. Berendt served as Managing Director of Research Corporation Technologies, Inc. From November 2000 to August 2004 Dr. Berendt served as Managing Director of AEA Investors LP. Dr. Berendt also worked for 18 years, from 1982 to 2000 in the pharmaceutical industry where he served in a number of senior management positions including Senior Vice President of Research for the Pharmaceutical Division of Bayer Corporation, and a Group Director of Drug Discovery at Pfizer, Inc.
Michael J. Berendt,1998年3月开始担任董事,是独立董事和投资人。2006年3月至2011年7月,他担任Aegera 疗法公司总裁兼CEO。2004年8月至2005年12月,他担任企业技术研究常务董事。2000年11月至2004年8月担任AEA投资公司常务董事。他在医药行业从事了18年,从1982年-2000年,担任各种高级管理职位,包括拜耳公司医药研究部门高级副总裁、辉瑞公司要去研发主管。他也曾担任Onyx制药公司、利亚德基因公司、催化剂生物科学和北极星神经学董事。
Michael J. Berendt has served as a Director of the Company since March 1998. Since December 2016 Dr. Berendt has been a life sciences industry consultant. From November 2013 to November 2016 Dr. Berendt was the Chief Executive Officer and Chief Scientist of Telesta Therapeutics. From July 2011 to November 2013 Dr. Berendt was a life sciences industry consultant. From March 2006 to July 2011 Dr. Berendt served as the President and Chief Executive Officer of Aegera Therapeutics Inc. From August 2004 to December 2005 Dr. Berendt served as Managing Director of Research Corporation Technologies, Inc. From November 2000 to August 2004 Dr. Berendt served as Managing Director of AEA Investors LP. Dr. Berendt also worked for 18 years, from 1982 to 2000 in the pharmaceutical industry where he served in a number of senior management positions including Senior Vice President of Research for the Pharmaceutical Division of Bayer Corporation, and a Group Director of Drug Discovery at Pfizer, Inc.
Edward Conard

Edward Conard,从1994年8月开始担任公司董事。他是独立董事和投资人。1993年3月至2007年12月,他担任贝恩公司常务董事。他之前是佩雷拉集团董事,是一家投资银行公司,专注于并购。他也曾是贝恩公司副总裁,负责各区运营。他还是 尤尼索斯国际公司董事。


Edward Conard has served as a Director of the Company since August 1994. He has been an independent director and investor since January 2008. Mr. Conard was a Managing Director of Bain Capital, LLC from March 1993 to December 2007. Mr. Conard was previously a Director of Wasserstein Perella & Co., Inc., an investment banking firm that specializes in mergers and acquisitions, and a Vice President of Bain & Company heading up the firm’s operations practice area.
Edward Conard,从1994年8月开始担任公司董事。他是独立董事和投资人。1993年3月至2007年12月,他担任贝恩公司常务董事。他之前是佩雷拉集团董事,是一家投资银行公司,专注于并购。他也曾是贝恩公司副总裁,负责各区运营。他还是 尤尼索斯国际公司董事。
Edward Conard has served as a Director of the Company since August 1994. He has been an independent director and investor since January 2008. Mr. Conard was a Managing Director of Bain Capital, LLC from March 1993 to December 2007. Mr. Conard was previously a Director of Wasserstein Perella & Co., Inc., an investment banking firm that specializes in mergers and acquisitions, and a Vice President of Bain & Company heading up the firm’s operations practice area.
Flemming Ornskov

Flemming Ornskov,2013年1月2日,他被任命为董事会成员,2013年4月30日被任命为首席执行官之前是首席执行官指定人。他给董事会带来了经营和医疗知识以及制药业的丰富国际、战略和经营经验。2010至2012年,他担任拜耳General and Speciality Medicine的首席营销官和战略营销全球主管;2008至2010年,担任Bausch & Lomb, Inc.的药物和非处方药全球总裁;2006年至2008年,先后担任Life-Cycle Pharma A/S的主席、总裁和首席执行官,2005至2006年,担任Ikaria, Inc.的总裁和首席执行官。在他的制药职业生涯早期,他就职于默克公司(Merck & Co., Inc.)和诺华制药(Novartis AG),在医院和医学院有辉煌的历史。他曾担任Evotec AG的非执行主席和PCI Biotech Holding ASA的非执行董事。他在哥本哈根大学(University of Copenhagen)获得医学博士学位,在欧洲工商管理学院(INSEAD)获得工商管理学硕士学位并在哈佛大学(Harvard University)获得公共卫生硕士学位。


Flemming Ornskov has served as the Chairman of our Supervisory Board since April 2019. He has served as the Chief Executive Officer of Galderma S.A. since October 2019. He served as Chief Executive Officer and Executive Director of Shire Plc from April 2013 to January 2019 when Shire was acquired by Takeda. He was appointed Non-Executive Director and Chairman of the Board of Recordati S.p.A. in February 2019. He has been a Non-Executive Director for the Waters Corporation since 2017. Previously, Dr. Ornskov was Non-Executive Chairman of Evotec from 2008 to 2012 and Non-Executive Director of PCI Biotech Holding from 2008 to 2013. From 2010 to 2013 he was Chief Marketing Officer and Global Head, General and Specialty Medicine at Bayer. He also previously held positions as Global President, Pharmaceuticals and Over-the Counter at Bausch & Lomb; Chairman, President and Chief Executive Officer of LifeCycle Pharma A/S, now Veloxis Pharma A/S; President and Chief Executive Officer of Ikaria; and various roles at Merck and Novartis. Dr. Ornskov received his M.D. from the University of Copenhagen, MBA from INSEAD, and Masters of Public Health from Harvard University.
Flemming Ornskov,2013年1月2日,他被任命为董事会成员,2013年4月30日被任命为首席执行官之前是首席执行官指定人。他给董事会带来了经营和医疗知识以及制药业的丰富国际、战略和经营经验。2010至2012年,他担任拜耳General and Speciality Medicine的首席营销官和战略营销全球主管;2008至2010年,担任Bausch & Lomb, Inc.的药物和非处方药全球总裁;2006年至2008年,先后担任Life-Cycle Pharma A/S的主席、总裁和首席执行官,2005至2006年,担任Ikaria, Inc.的总裁和首席执行官。在他的制药职业生涯早期,他就职于默克公司(Merck & Co., Inc.)和诺华制药(Novartis AG),在医院和医学院有辉煌的历史。他曾担任Evotec AG的非执行主席和PCI Biotech Holding ASA的非执行董事。他在哥本哈根大学(University of Copenhagen)获得医学博士学位,在欧洲工商管理学院(INSEAD)获得工商管理学硕士学位并在哈佛大学(Harvard University)获得公共卫生硕士学位。
Flemming Ornskov has served as the Chairman of our Supervisory Board since April 2019. He has served as the Chief Executive Officer of Galderma S.A. since October 2019. He served as Chief Executive Officer and Executive Director of Shire Plc from April 2013 to January 2019 when Shire was acquired by Takeda. He was appointed Non-Executive Director and Chairman of the Board of Recordati S.p.A. in February 2019. He has been a Non-Executive Director for the Waters Corporation since 2017. Previously, Dr. Ornskov was Non-Executive Chairman of Evotec from 2008 to 2012 and Non-Executive Director of PCI Biotech Holding from 2008 to 2013. From 2010 to 2013 he was Chief Marketing Officer and Global Head, General and Specialty Medicine at Bayer. He also previously held positions as Global President, Pharmaceuticals and Over-the Counter at Bausch & Lomb; Chairman, President and Chief Executive Officer of LifeCycle Pharma A/S, now Veloxis Pharma A/S; President and Chief Executive Officer of Ikaria; and various roles at Merck and Novartis. Dr. Ornskov received his M.D. from the University of Copenhagen, MBA from INSEAD, and Masters of Public Health from Harvard University.

高管简历

中英对照 |  中文 |  英文
Christopher J. O’Connell

Christopher J. O’Connell先生,为Medtronic,Inc.之执行副总裁及美敦力之恢复性治疗集团之总裁.O`Connell先生负责全球美敦力之脊柱╱骨科及生物制剂、神经调节、糖尿病及手术技术业务单位.O`Connell先生为本集团提供整体策略方向及全球营运监督相关业务,以及以美敦力之整体策略领导整合本集团活动.O`Connell先生于一九九四年加入美敦力,并曾于该公司担任多项领导职位.于二零零六年至二零零九年期间,O`Connell先生担任驻加利福利亚Northridge糖尿病业务之高级副总裁及总裁.于二零零五年至二零零六年期间,彼担任驻华盛顿Redmond之Medtronic Physio-Control之总裁.O`Connell先生亦曾于美敦力之心脏节律疾病管理业务担任重要领导职务,包括销售及市场推广副总裁及病人管理业务之副总裁╱总经理.此外,O`Connell先生作为企业策略副总裁及投资者关系董事领导重要公司职能.于加入美敦力前,O`Connell先生于化工银行之公司财务单位任职.O`Connell先生于一九八九年在西北大学获得学士学问,并于一九九四年在哈佛大学获得工商管理硕士学位.


Christopher J. O’Connell has been Executive Vice President and Group President, Restorative Therapies Group since August 2009. Prior to that, he was Senior Vice President and President, Diabetes from October 2006 to August 2009 President of Medtronic’s Emergency Response Systems division from May 2005 to October 2006 and Vice President of Sales and Marketing of Medtronic’s Cardiac Rhythm Disease Management division from November 2001 to May 2005. Mr. O’Connell has served in various management positions since joining the Company in 1994.
Christopher J. O’Connell先生,为Medtronic,Inc.之执行副总裁及美敦力之恢复性治疗集团之总裁.O`Connell先生负责全球美敦力之脊柱╱骨科及生物制剂、神经调节、糖尿病及手术技术业务单位.O`Connell先生为本集团提供整体策略方向及全球营运监督相关业务,以及以美敦力之整体策略领导整合本集团活动.O`Connell先生于一九九四年加入美敦力,并曾于该公司担任多项领导职位.于二零零六年至二零零九年期间,O`Connell先生担任驻加利福利亚Northridge糖尿病业务之高级副总裁及总裁.于二零零五年至二零零六年期间,彼担任驻华盛顿Redmond之Medtronic Physio-Control之总裁.O`Connell先生亦曾于美敦力之心脏节律疾病管理业务担任重要领导职务,包括销售及市场推广副总裁及病人管理业务之副总裁╱总经理.此外,O`Connell先生作为企业策略副总裁及投资者关系董事领导重要公司职能.于加入美敦力前,O`Connell先生于化工银行之公司财务单位任职.O`Connell先生于一九八九年在西北大学获得学士学问,并于一九九四年在哈佛大学获得工商管理硕士学位.
Christopher J. O’Connell has been Executive Vice President and Group President, Restorative Therapies Group since August 2009. Prior to that, he was Senior Vice President and President, Diabetes from October 2006 to August 2009 President of Medtronic’s Emergency Response Systems division from May 2005 to October 2006 and Vice President of Sales and Marketing of Medtronic’s Cardiac Rhythm Disease Management division from November 2001 to May 2005. Mr. O’Connell has served in various management positions since joining the Company in 1994.
Michael C. Harrington

Michael C. Harrington2016年2月被任命为全球市场的高级副总裁。1987年,Harrington博士在Waters担任多个高级职位,包括欧洲和亚太地区业务的副总裁,美国市场销售业务的高级总监,美国化学销售董事和Phase Separations的总经理。加入Waters之前,Harrington博士曾在Celsis, Inc.担任高级销售职位。


Michael C. Harrington was appointed Senior Vice President, Global Markets in February 2016. Dr. Harrington joined Waters Corporation in 1987 and has held several senior positions with Waters Corporation, including Vice President, Europe and Asia Pacific Operations, Senior Director of US Sales Operations, Director of US Chemistry Sales and General Manager of Phase Separations. Prior to joining Waters Corporation, Dr. Harrington held senior sales positions at Celsis, Inc.
Michael C. Harrington2016年2月被任命为全球市场的高级副总裁。1987年,Harrington博士在Waters担任多个高级职位,包括欧洲和亚太地区业务的副总裁,美国市场销售业务的高级总监,美国化学销售董事和Phase Separations的总经理。加入Waters之前,Harrington博士曾在Celsis, Inc.担任高级销售职位。
Michael C. Harrington was appointed Senior Vice President, Global Markets in February 2016. Dr. Harrington joined Waters Corporation in 1987 and has held several senior positions with Waters Corporation, including Vice President, Europe and Asia Pacific Operations, Senior Director of US Sales Operations, Director of US Chemistry Sales and General Manager of Phase Separations. Prior to joining Waters Corporation, Dr. Harrington held senior sales positions at Celsis, Inc.
Robert G. Carson
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Francis Kim
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Sherry L. Buck

Sherry L. Buck ,于2012年8月1日加入Libbey,担任副总裁以及财务总监。她从Whirlpool 公司 (NYSE: WHR)转到了Libbey公司,她是于1993年加入Whirlpool并自2010年10月以来最近担任全球产品和企业成本管理首席执行官的。在2009-2010年10月以来,她曾是财务副总裁(美国),以及在2007-2008年末,她曾担任成本管理副总裁。他先前在Whirlpool的职位包括财务副总裁(国际)以及企业绩效管理副总裁。


Sherry L. Buck joined Libbey as Vice President, Chief Financial Officer on August 1, 2012. Ms. Buck came to Libbey from Whirlpool Corporation (NYSE: WHR), which she joined in 1993 and where she most recently served as Chief Financial Officer, Global Product and Enterprise Cost Leadership, since October 2010. From 2009 to October 2010, Ms. Buck was Vice President, Finance - U.S., and from 2007 to the end of 2008 she served as Vice President, Cost Leadership. Previous roles with Whirlpool included Vice President, Finance - International and Corporate Vice President, Business Performance Management.
Sherry L. Buck ,于2012年8月1日加入Libbey,担任副总裁以及财务总监。她从Whirlpool 公司 (NYSE: WHR)转到了Libbey公司,她是于1993年加入Whirlpool并自2010年10月以来最近担任全球产品和企业成本管理首席执行官的。在2009-2010年10月以来,她曾是财务副总裁(美国),以及在2007-2008年末,她曾担任成本管理副总裁。他先前在Whirlpool的职位包括财务副总裁(国际)以及企业绩效管理副总裁。
Sherry L. Buck joined Libbey as Vice President, Chief Financial Officer on August 1, 2012. Ms. Buck came to Libbey from Whirlpool Corporation (NYSE: WHR), which she joined in 1993 and where she most recently served as Chief Financial Officer, Global Product and Enterprise Cost Leadership, since October 2010. From 2009 to October 2010, Ms. Buck was Vice President, Finance - U.S., and from 2007 to the end of 2008 she served as Vice President, Cost Leadership. Previous roles with Whirlpool included Vice President, Finance - International and Corporate Vice President, Business Performance Management.